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ABSTRACT: Synthetic cannabinoids (SCs) are the largest
group of compounds currently monitored in Europe by the EU
Early Warning System on new psychoactive substances.
Emerging recreational use of these products has led to
multiple cases of adverse health eﬀects and even death. In
contrast to marijuana, where Δ9-tetrahydrocannabinol
(Δ9THC) is metabolized to only one major active metabolite,
it has been reported that several major phase I metabolites of
SCs remain biologically active, exerting cannabinoid (CB)
receptor aﬃnity, potency, and eﬃcacy greater than those of
Δ9THC. It is therefore reasonable that more SCs can also be
biotransformed into molecules with various levels of CB
activity. Here, we developed and applied a new G-protein coupled receptor (GPCR) activation assay based on NanoLuc binary
technology (Promega). More speciﬁcally, by demonstrating CB1 and CB2 receptor activation by JWH-018 and a selection of its
metabolites, we are the ﬁrst to show the suitability of the newly developed bioassay for monitoring GPCR-mediated activity. We
also successfully applied this reporter system to evaluate the in vitro activity of JWH-122, JWH-210, and PB-22, their 5-ﬂuoro
analogues (MAM-2201, EAM-2201, and 5F-PB-22, respectively), and their main phase I metabolites. By doing so, we
demonstrate that several major metabolites of these SCs retain their activity at cannabinoid receptors. All of these active
metabolites may prolong the parent compound’s psychotropic and physiological eﬀects and may contribute to its toxicity proﬁle.
We also demonstrate a proof of concept of the applicability of the newly developed bioassay for screening urine for CB receptor
activity exerted by SCs.
Synthetic cannabinoid (CB) receptor agonists, commonlyreferred to as synthetic cannabinoids (SCs), are the largest
group of compounds currently monitored in Europe by the EU
Early Warning System on new psychoactive substances (NPS).1
Although they are marketed as a “safe” and “legal” alternative to
marijuana, recent reports indicate that many of these
compounds may produce serious adverse health eﬀects.2,3
SCs were originally synthesized by research laboratories to
investigate the endocannabinoid system or as potential
therapeutic drugs because they interact with cannabinoid
receptors CB1 and CB2. Currently, however, they have
reappeared through the Internet as designer drugs, so-called
“legal highs”.4−6 In contrast to the major psychoactive
constituent of marijuana, Δ9-tetrahydrocannabinol (Δ9THC),
which is a partial agonist at both receptors, SCs may act as full
agonists and may be selective for one receptor subtype.7 The
psychoactive eﬀects derive from agonistic activity at CB1,
predominantly found in the central nervous system. CB2
receptors are mainly associated with the immune system, but
they are also expressed at a lower density in the brain.8−10 CB1
and CB2 are G-protein coupled receptors (GPCRs). They are
coupled through the Gi/o family of G-proteins to signal
transduction mechanisms that include inhibition of adenylyl
cyclase, activation of mitogen-activated protein kinase,
regulation of calcium and potassium channels (CB1 only),
and other signal transduction pathways. GPCRs are rapidly
desensitized by recruitment of the cytosolic protein β-arrestin 2
(βarr2).11
Unlike the widespread use of marijuana, which poses only
relatively limited acute toxicity, serious adverse eﬀects, often
requiring medical attention, are not uncommon with SC
consumption. Indeed, the relative risk of seeking emergency
medical treatment following the use of SCs has been reported
to be 30 times higher than that associated with the use of
natural forms of cannabis.12 Observed eﬀects include central
eﬀects (psychosis, paranoia, agitation, seizures, and anxiety),
cardiotoxic eﬀects, acute kidney failure, respiratory depression,
rhabdomyolysis, withdrawal symptoms, coma, and even
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death.4,7,13,14 The reason for the more profound adverse eﬀects
is not fully clear. It is known that the majority of SCs exhibits a
higher aﬃnity, potency, and eﬃcacy at both the CB1 and CB2
receptors compared to those of Δ9THC.7 As SC products may
be a combination of several compounds, it is possible that the
resulting activation of CB1 and/or CB2 produces stronger
physiological and psychotropic eﬀects. Another diﬀerence
between Δ9THC and SCs is their metabolism. In contrast to
marijuana, where Δ9THC is metabolized to only one major
active metabolite,15 it has been reported that several major
metabolites of JWH-018, JWH-073, AM-2201, UR-144, and
XLR-11 are still biologically active, exerting greater CB1
aﬃnity, potency, and eﬃcacy than Δ9THC, both in vitro and in
vivo.16−19 The metabolites of JWH-018 and JWH-073 also
maintain their in vitro activity at CB2.20 It is therefore
reasonable to assume that other SCs are also biotransformed
into molecules with various levels of activity at the CB
receptors. These active metabolites may prolong the parent
compound’s psychotropic and physiological eﬀects and may
contribute to its toxicity proﬁle. Greater knowledge of the
activity of relevant metabolites of a wider set of SCs may allow
us to gain better insight into the contribution of these active
metabolites to the toxicity observed with SCs. Although there
may be diﬀerences between in vitro and in vivo activities, these
seem to be correlated; therefore, in vitro assays may serve this
purpose.
Current methods used in the literature to determine the in
vitro activity of SCs (and their metabolites) are the [35S]GTPγS
binding assay,17−26 a quantitative internalization assay,27,28
adenylyl cyclase assays,20,29,30 and the commercial FLIPR
membrane potential assay from Molecular Devices.16,30,31
There are also commercially available β-arrestin recruitment
assays, which have been evaluated for CB1 and CB2
cannabinoid receptors. These include the imaging-based
Redistribution and Transﬂuor assays (from Thermo Fisher
Scientiﬁc and Molecular Devices, respectively) and the
nonimaging-based Tango and PathHunter assays (from
Thermo Fisher Scientiﬁc and DiscoveRx, respectively).32,33
The GTPγS binding assay directly measures the guanine
nucleotide exchange of G-proteins, an early event after GPCR
activation. Although this assay could be applied (because CB
receptors are Gi/o-coupled), the radioactivity, high back-
ground, and requirement for a ﬁltration step are important
drawbacks.34−36 The quantitative internalization assay, which
evaluates the remaining percentage of cell surface receptors via
antibody staining as a measurement of receptor activation, is
not preferred as it is labor-intensive due to the multiple washing
and binding steps. Adenylyl cyclase assays are based on the
quantiﬁcation of second messenger cAMP. However, in the
case of Gi/o-coupled receptors, prestimulation is required (e.g.,
with forskolin, a direct activator of the adenylyl cyclase).35,36
The FLIPR membrane potential assay is designed to measure
intracellular changes in calcium levels by using calcium-sensitive
ﬂuorescent dyes. The rapid and transient calcium ﬂux makes
the assay unsuitable for detecting slow binding agonists. Also,
the use of a ﬂuorescent readout may lead to false positive
signals due to possible interference from other compounds.35,36
The Redistribution and Transﬂuor assays evaluate receptor
activation by monitoring receptor internalization via fusion
proteins with green ﬂuorescent protein (GFP). While a beneﬁt
of these assays is the real-time measurement and visualization of
the GFP fusion protein during the internalization process, they
require a dedicated imaging system and oﬀer a relatively low
throughput. In the Tango assay, GPCR activation is evaluated
by the release of a transcription factor, which leads to
expression of a reporter protein that can be quantiﬁed.
Although reporter gene assays are sensitive, there are some
concerns. These include the need for long incubation times,
diﬃculties in antagonist detection due to reporter accumu-
lation, and the high potential for false positives as reporter
protein expression is a distal event to receptor activation. In the
PathHunter assay, the β-arrestin−receptor interaction is
measured via enzyme fragment complementation of β-
galactosidase. The PathHunter assay, just as the Tango assay,
can be read on a standard multimode reader and is easily
adaptable for high-throughput screening, but its advantage over
the Tango assay is that the detection is proximal to the
receptor. The downsides of the PathHunter assay are its lack of
ﬂexibility for the end user and the limited time window for
detection as the β-arrestin−receptor interaction is measured
only 90−120 min after stimulation with the test com-
pound.33,35−37
Here, we developed and applied a new GPCR activation
assay based on NanoLuc binary technology (Promega). This
technology has already successfully been applied to study
protein−protein interactions.38 We report on the application of
this assay for the monitoring of GPCR activation, via ligand-
induced interaction of βarr2 with a given GPCR. More
speciﬁcally, by demonstrating activation of CB1 and CB2
cannabinoid receptors by JWH-018 and a selection of its
metabolites, we are the ﬁrst to show the suitability of the newly
developed bioassay for activity proﬁling of GPCR ligands. Next,
we applied this reporter system to evaluate the in vitro activity
of JWH-122, JWH-210, and PB-22, their 5-ﬂuoro analogues
(MAM-2201, EAM-2201, and 5F-PB-22, respectively), and
their main phase I metabolites (Figure 1). By doing so, we
demonstrate that several major metabolites of these SCs retain
their activity at CB receptors. We also demonstrate a proof of
concept of the applicability of the newly developed bioassay for
detecting the presence of CB receptor activating compounds,
notably SCs (and their metabolites), in urine.
Figure 1. Structures of SCs and metabolites. (A) SCs belonging to the
aminoalkylindole family: JWH-018, JWH-122, MAM-2201, JWH-210,
and EAM-2201. (B) PB-22 and 5F-PB-22, belonging to the
indolecarboxylate family.
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■ MATERIALS AND METHODS
Chemicals and Reagents, Plasmids and Constructs,
and Cell Culture and Transfection. Chemicals and reagents
were obtained as described in the Supporting Information
(Data S1). Expression vectors encoding human CB1 or CB2
receptor or β-arrestin 2, fused via a ﬂexible linker to the
subunits of NanoLuc luciferase (LgBiT or SmBiT), were
generated using standard molecular biology techniques, as
outlined in Supporting Information Data S1. These constructs
were used to transiently transfect human embryonic kidney
(HEK) 293T cells, which were seeded in poly-D-lysine-coated
96-well plates at 5 × 104 cells/well and incubated overnight
before performing the assay. More details can be found in
Supporting Information Data S1.
Cannabinoid Reporter Assay. Forty-eight hours after
transfection, the cells were washed twice with Opti-MEM I
reduced serum medium to remove any remaining FBS, and 100
μL of Opti-MEM I was added. The Nano-Glo Live Cell
reagent, a nonlytic detection reagent containing the cell-
permeable furimazine substrate, was prepared by diluting the
Nano-Glo Live Cell substrate 20× using Nano-Glo LCS
Dilution buﬀer, and 25 μL was added to each well.
Subsequently, the plate was placed in a GloMAX96 (Promega).
Luminescence was monitored during the equilibration period
until the signal was stabilized (30−45 min). For agonist
experiments, we added 10 μL per well of test compounds,
present as 13.5× stocks in 50% methanol in Opti-MEM I.
Luminescence was continuously detected for 120 min. For
antagonist experiments, 5 μL of the antagonist stock solution
(26× stock solution in 50% methanol in Opti-MEM I) was
incubated for 5 min before adding 5 μL of agonist (27× stock
solution in 50% methanol in Opti-MEM I). The luminescence
was continuously detected for 120 min. Solvent controls were
run in all experiments; the ﬁnal concentration of methanol
(3.7%) did not pose a problem given the advantage of the short
readout time of the assay.
Statistical Analysis. Curve ﬁtting and statistical analyses
were performed using GraphPad Prism software (San Diego,
CA, USA). To select the optimal conﬁguration for the CB
reporter assay for both CB receptors, results are represented as
mean area under the curve (AUC) ± standard error of mean
(SEM) with six replicates for each data point (unless stated
otherwise) and were statistically analyzed using Student’s t test
after F-test and Grubbs’ outliers test (α = 0.05). Curve ﬁtting of
concentration−eﬀect curves via nonlinear regression was
employed to determine EC/IC50 (a measure of potency). To
evaluate the activity of the diﬀerent SCs and their metabolites,
results are represented as the percentage (%) CB activation
(relative to the receptor activation of JWH-018) ± SEM, with
at least three replicates for each data point. Here, the absolute
signals were baseline-corrected by subtracting the vehicle
control samples and were corrected for the interwell variability
before the AUC calculations (see Supporting Information Data
S2). A one-way ANOVA, followed by Dunnett’s post hoc test,
was used to determine statistical signiﬁcance (P < 0.05) (i)
between all compounds and the reference compound JWH-
018, (ii) within a group between a parent compound and the
other compounds in that group (e.g., all compounds related to
JWH-122 vs JWH-122), and (iii) between the signals obtained
from the compounds and those from solvent controls. To plot
the activity proﬁles of the natural cannabinoids and urinary
samples, the normalized raw data are shown (see Supporting
Information Data S2).
Urine Sample Preparation. For conjugate cleavage, 0.5
mL of phosphate buﬀer, pH 6, and 30 μL of β-glucuronidase
were added to 0.5 mL of urine, followed by a 1 h incubation at
45 °C. Then, 1.5 mL of ice-cold acetonitrile and 0.5 mL of 10
M ammonium formate were added. The mixture was shaken
and centrifuged. One milliliter of the organic phase was
transferred to a separate vial and evaporated to dryness under a
stream of nitrogen. For analysis with the applied CB reporter
assay, the evaporated extract was reconstituted in 100 μL of
Opti-MEM I/MeOH (50/50, v/v), of which 10 μL was used
per well (see the Cannabinoid Reporter Assay section). For
LC-MS/MS analysis, another 0.5 mL aliquot was spiked with
internal standards (2 ng/mL; see Supporting Information Data
S3) and processed as described above. The residue was
reconstituted in 200 μL of mobile phase A/B (50/50, v/v)
prior to LC-MS/MS analysis.
LC-ESI-MS/MS Analysis of Urine Samples. Quantiﬁca-
tion of SC metabolites in a genuine urine sample was
performed by applying a semiquantitative LC-MS/MS method.
Selectivity and speciﬁcity were tested by analyzing six blank
samples. Linearity was given for all analytes from 0.01 to 10.0
ng/mL. The lowest calibrator level was deﬁned as the lower
limit of quantiﬁcation (LLOQ). Precision (<15%) and accuracy
(<±15%) were assessed by analysis of control samples.
Concentrations below the calibration range were extrapolated
using the peak area ratio of the lowest calibrator and were
reported only if the identiﬁcation criteria were fulﬁlled
(retention time, signal-to-noise ratio > 3:1, qualiﬁer ion/
quantiﬁer ion ratio). Matrix eﬀects were not assessed since
semiquantitative values were considered acceptable for the
proof-of-concept comparison with the qualitative results of the
applied reporter assay. Settings used for the chromatographic
separation and the tandem mass spectrometry analysis are
described elsewhere.39 For details on the optimized MS settings
of the quantiﬁed analytes and internal standards, see
Supporting Information Data S3.
■ RESULTS AND DISCUSSION
Design of the CB Reporter Assay. NanoLuc binary
technology utilizes a structural complementation-based ap-
proach to monitor protein interactions within living cells. It
makes use of inactive subunits of NanoLuc luciferase, Large BiT
(LgBiT; 18 kDa) and Small BiT (SmBiT; 1 kDa), which are
coupled to two proteins of interest. Protein interaction
promotes structural complementation of the subunits, thereby
restoring NanoLuc luciferase activity, which generates a
bioluminescent signal in the presence of the furimazine
substrate. To monitor GPCR activation, we made use of its
stimulation-dependent interaction with the cytosolic adaptor
protein βarr2, which mediates receptor desensitization and
internalization in a widely distributed manner throughout the
GPCR family.40−42 Here, we aimed at establishing assays
capable of monitoring activation of CB1 and CB2 receptors
using a panel of SCs and their metabolites. To this end, we
designed constructs in which the LgBiT or SmBiT subunit is
coupled to the CB1 or CB2 C-terminus and to the N- or C-
terminus of βarr2. To assess the functional complementation of
the LgBiT and SmBiT fusion proteins upon GPCR activation,
all possible combinations were tested by stimulation with a
known agonist, JWH-018 (Figure 2).
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Whenever both the CB and βarr2 fusion proteins were
present together, unstimulated cells readily showed a signal
above background (i.e., the signal when only the CB fusion
protein was present), pointing at some level of constitutive
CB−βarr2 interaction (open bars in Figure 2A). Regardless of
the combination of CB and βarr2 fusion proteins used, a
signiﬁcant increase in signal was observed upon agonist
stimulation (closed bars in Figure 2A). The highest signals
were observed for the CB−SmBiT/LgBiT−βarr2 combina-
tions. For CB2, this combination also yielded the largest
increase (2.27-fold) when comparing stimulated vs non-
stimulated cells. For CB1, however, the combination of
CB1−LgBiT/SmBiT−βarr2, although it gave somewhat lower
absolute signals, yielded the largest increase (3.81-fold)
following activation. Hence, further experiments were per-
formed with cells that were transiently transfected with either
the CB1−LgBiT/SmBiT−βarr2 combination or the CB2−
SmBiT/LgBiT−βarr2 combination (Figure 2B).
Concentration Dependence of the CB Reporter
Assays. Upon stimulation with a known agonist, JWH-018,
CB1−LgBiT and CB2−SmBiT showed a concentration-
dependent interaction with SmBiT−βarr2 and LgBiT−βarr2,
respectively, with EC50 values of 38.2 and 12.8 nM (Table 1
and Figure 3A,B). Also, for other synthetic cannabinoids,
concentration-dependence was obtained and EC50 values were
determined as a measure of relative potency (Table 1; graphs
are shown in Supporting Information Data S4). Although it is
diﬃcult to compare EC50 values from diﬀerent assays (due to
diﬀerent experimental setups), our values are in line with those
found in the literature. More speciﬁcally, reported EC50 values
for CB1 of JWH-018, JWH-122, and JWH-210 ([35S]GTPγS
binding assay: 36, 32.9, and 20.4 nM, respectively)24 are in line
with the EC50 values we obtained, ranging from 25.3 to 71.7
nM (Table 1). For PB-22 and 5F-PB-22, which are known to
have an even higher potency,16 we obtained subnanomolar
EC50 values using the newly developed assay. Again, these EC50
values match the order of magnitude of those found in the
literature (FLIPR membrane potential assay: CB1 5.1 and 2.8
nM vs 102 nM for JWH-018; CB2 37 and 11 nM vs 133 nM for
JWH-018).16 Our data are also in line with the observation by
Banister et al. that terminal ﬂuorination of the N-pentyl results
in increased CB receptor potency.16 For CB1, the parent
compounds JWH-122, JWH-210, and PB-22 and their 5-ﬂuoro
analogues (MAM-2201, EAM-2201 and 5F-PB-22, respec-
tively) showed CB1 activation that was signiﬁcantly higher than
the reference JWH-018 (graphs are shown in Supporting
Information Data S4). This may point at an intrinsic high
eﬃcacy of these compounds or, alternatively, to more eﬃcient
recruitment of βarr2 upon receptor activation, or both. The
JWH-018-induced recruitment of βarr2 to CB1 was blocked by
Rimonabant, a selective CB1 antagonist, in a concentration-
dependent manner (Figure 3C), demonstrating the speciﬁcity
of the assay. Curve ﬁtting of concentration−eﬀect curves via
nonlinear regression was employed to determine the IC50 of
Rimonabant, which was 11.4 nM (95% CI proﬁle likelihood:
8.6−15.1 nM) and is in line with the IC50 value of 17.6 nM
(Eu-GTPγS binding assay) found in the literature.43
Application of the CB Reporter Assays on SCs and
Their Main Phase I Metabolites. JWH-018. JWH-018 was
the ﬁrst SC reported in Germany in December 2008 as one of
the active components of the herbal blend “Spice”.5,6 It is a
naphthoylindole, belonging to the aminoalkylindole family.
Although its chemical structure diﬀers substantially from that of
Δ9THC, it produces similar eﬀects and has been reported to be
more potent than Δ9THC (data shown in Supporting
Information Data S5). Importantly, several metabolites of
JWH-018 have been reported to have partial to full agonist
activity at CB1 and CB2.18−20 To further validate our newly
developed CB reporter assay, we applied it to JWH-018 and a
selection of its metabolites, reported as the major phase I
metabolites occurring in urine, i.e., the 4- and 5-OH-pentyl, 5-
and 6-OH-indole, and the N-pentanoic acid metabolites.44−46
Figure 2. Comparison of the diﬀerent combinations at both CB
receptors. (A) CB reporter assays for CB1 (upper graph) and CB2
(lower graph). A stimulation-dependent interaction of βarr2 with both
CB receptors was consistently observed. No ligand-dependent eﬀects
could be detected for the single CB fusion protein. Data are given as
the mean AUC ± SEM (n = 5−6); *P ≤ 0.01, **P ≤ 0.001, ***P ≤
0.0001 (two-sided t-test). (B) Optimal design of the CB reporter
assays for CB1 and CB2: CB1−LgBiT/SmBiT−βarr2 and CB2−
SmBiT/LgBiT−βarr2.
Table 1. EC50 Values of Diﬀerent SCs
a
drug CB1 EC50 (nM) CB2 EC50 (nM)
JWH-018 38.2 (27.1−55.7) 12.8 (5.6−26.0)
JWH-122 71.7 (52.3−104.4) 9.2 (5.1−15.9)
MAM-2201 60.5 (44.3−87.5) 2.7 (1.1−5.1)
JWH-210 25.3 (18.3−34.7) 17.5 (10.1−29.1)
EAM-2201 4.8 (3.2−7.2) 3.7 (1.9−6.5)
PB-22 0.86 (0.53−1.33) 0.82 (0.30−1.46)
5F-PB-22 0.84 (0.51−1.40) 0.70 (0.47−0.97)
aEC50 values are presented as a measure of potency. Data are given as
EC50 values (95% CI proﬁle likelihood).
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For each of these compounds, we assessed βarr2 recruitment
to either the CB1 or CB2 receptor at an arbitrarily chosen
concentration of 1 μM, corresponding to a receptor saturating
concentration of JWH-018. Unlike JWH-018 and all of the
monohydroxylated metabolites, which activated both CB
receptors (Figure 4, Supporting Information Data S6), the N-
pentanoic acid metabolite did not induce a signiﬁcant diﬀerence
from basal levels at both receptors, which is in line with its
reported lack of aﬃnity for CB1 and CB2 receptors (Ki for CB1
and CB2 ≥ 10 000 nM).18,20
The extent of CB1 and CB2 activation varied for individual
metabolites. For CB1, there was no statistical diﬀerence in the
level of receptor activation by the 4-OH-pentyl and 5-OH-
indole metabolites when compared to the JWH-018 parent
compound. The two other hydroxylated metabolites (5-OH-
pentyl and 6-OH-indole metabolites) produced signiﬁcantly
less CB1 activation, 20.7 and 24.1% relative to JWH-018,
respectively (Figure 4A and Supporting Information Data S6).
For CB2, all hydroxylated metabolites yielded a signal that was
not signiﬁcantly diﬀerent from that obtained after stimulation
with JWH-018, indicating that these metabolites also retain
their activity at CB2 (Figure 4B), which is consistent with the
literature.18−20 It is worth noting that, when compared to the
literature, there is no perfect overlay in the relative activity of
the metabolites. Several reasons may account for these more
subtle diﬀerences, most notably the diﬀerent experimental
setups that have been used (e.g., [35S]GTPγS binding assay and
adenylyl cyclase assay vs βarr2 recruitment).18−20
JWH-122, JWH-210, MAM-2201, and EAM-2201. JWH-122
and JWH-210 and their 5-ﬂuoro analogues, MAM-2201 and
EAM-2201, respectively, belong to the naphthoylindole family.
They only diﬀer from JWH-018 by the addition of a methyl/
ethyl on the naphthyl moiety (Figure 1). These SCs became
popular in 2010−2011 after the prohibition of the “ﬁrst
generation” of SCs (e.g., JWH-018, JWH-073).47,48 The shift to
these agonists, some of which are more potent than JWH-018
(Table 1), has led to more cases with serious symptoms,
including a reported fatality of MAM-2201 poisoning.49−52
Biotransformation of JWH-122 and MAM-2201 leads to
common metabolites: the 5-OH-pentyl and N-pentanoic acid
JWH-122 metabolites. MAM-2201 also produces trace amounts
of the 4-OH-pentyl-MAM-2201 metabolite.53 Both in vitro
metabolism studies53 and analyses of authentic urine samples
from users (unpublished observations)53 demonstrated that the
5-OH-pentyl-JWH-122 metabolite was the primary phase I
metabolite of MAM-2201, whereas the 4-OH-pentyl-JWH-122
metabolite was predominant and exclusive in JWH-122
metabolism.53 From the available reference standards for
metabolites of JWH-210, the 4-OH-pentyl metabolite was the
most prevalent phase I metabolite in urine. The other phase I
metabolites that were present in decreasing abundance are the
5-OH-indole and 5-OH-pentyl metabolites. For EAM-2201, the
5-OH-pentyl-JWH-210 metabolite was the most abundant
phase I metabolite in the urine of users, followed by the N-
pentanoic acid JWH-210 metabolite (unpublished observa-
tions). Since the activity of these metabolites at CB receptors is
not known, we evaluated these with our new bioassay. Again, all
compounds were tested at 1 μM, with JWH-018 as a reference.
JWH-122, MAM-2201, JWH-210, EAM-2201, and all of the
monohydroxylated metabolites showed signiﬁcant activation of
both receptors. The N-pentanoic acid JWH-122 metabolite did
not induce a signiﬁcant diﬀerence from basal levels at both
receptors, but, unexpectedly, the N-pentanoic acid JWH-210
metabolite did show CB2 receptor activation, which, although
somewhat lower, was not signiﬁcantly diﬀerent from the parent
compound, JWH-210. (Figure 5A,B and Supporting Informa-
tion Data S6). The signal obtained for almost all hydroxylated
metabolites was not signiﬁcantly diﬀerent from that induced by
the corresponding parent compounds, JWH-122 and JWH-210.
Only 5-OH-pentyl-JWH-122 and 5-OH-indole-JWH-210
yielded signals that were signiﬁcantly lower, but they still
induced levels of CB1 activation that were not statistically
diﬀerent from our reference compound, JWH-018. For CB2,
there was no statistical diﬀerence in the level of receptor
Figure 3. Concentration-dependent interaction of CB1 (A) and CB2 (B) with βarr2 upon stimulation with JWH-018. (C) Interaction of βarr2 with
the CB1 receptor, induced by JWH-018 at its ED80 concentration, was blocked by Rimonabant, a selective CB1 antagonist, in a concentration-
dependent manner. AUC, area under the curve (luminescence over time). Data are given as the mean AUC ± SEM (n = 5−6).
Figure 4. Activation of CB1 receptor (A) and CB2 receptor (B) by
JWH-018 and its major phase I metabolites at 1 μM. Bars assigned
with (a) above the error bars are signiﬁcantly diﬀerent from the
reference compound JWH-018 (P ≤ 0.05, one-way ANOVA with
Dunnett’s multiple comparison post hoc test). Bars assigned with an
(*) are not signiﬁcantly diﬀerent from basal levels. Data are given as
mean % CB receptor activation (in comparison to the receptor
activation of the reference, JWH-018) ± SEM (n = at least 3
replicates).
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activation produced by the reference compound (JWH-018),
JWH-122, MAM-2201, JWH-210, EAM-2201, and their
monohydroxylated metabolites.
PB-22 and 5F-PB-22. PB-22 (also named QUPIC) and 5F-
PB-22 belong to the quinolin-8-yl indolecarboxylate family,
diﬀering from the earlier generation naphthoylindoles by the
replacement of the naphthalene group with an ester-linked
quinolin-8-yl moiety (Figure 1). These compounds were ﬁrst
reported to the EMCDDA in November 2012 following their
seizure by Finnish customs authorities.6 PB-22 and 5F-PB-22
have been implicated in clinical reports of seizure,54,55 with 5F-
PB-22 having been associated with several adverse reactions,
comprising anxiety, paranoia, headache, vomiting, sweating, and
nausea.56 5F-PB-22 has also been detected in several fatal
intoxications in the USA.57 PB-22 and 5F-PB-22 are known to
be very potent SCs, both possessing subnanomolar potency at
CB receptors (Table 1), but nothing is known about the
activities of their metabolites. The metabolism of PB-22 and
5F-PB-22 has primarily been investigated via in vitro
metabolism studies.58−60 After examining authentic urine
samples from users who consumed PB-22 and 5F-PB-22, we
selected some metabolites to assess their activity at CB
receptors. For PB-22, the 3-carboxyindole was the major
phase I metabolite, with the 4-OH-pentyl metabolite usually
being the second most prevalent. A similar metabolic proﬁle
was seen for 5F-PB-22, with the 3-carboxyindole as most
prominent and the 5-OH-pentyl as second most abundant
phase I metabolite.
The reporter assay was used to evaluate the intrinsic activity
at the CB1 and CB2 receptors of PB-22, 5F-PB-22, and all of
the above-mentioned metabolites, as well as that of the N-
pentanoic acid metabolite, which is also found in most urine
samples (unpublished observations), all at a ﬁxed concentration
of 1 μM. PB-22 and 5F-PB-22 showed signiﬁcantly stronger
receptor activation at both CB receptors in comparison to the
reference, JWH-018: 2.87- and 2.79-fold increases at the CB1
receptor and 1.38- and 1.32-fold increases at the CB2 receptor,
respectively (Figure 5A,B and Supporting Information Data
S6). The capability of the major phase I metabolites 3-
carboxyindole-PB-22 and 3-carboxyindole-5F-PB-22 to activate
the CB receptors did not diﬀer signiﬁcantly from basal levels.
There was also no antagonistic activity observed for these two
compounds (Supporting Information Data S7), indicating that
the 3-carboxyindole metabolites do not induce eﬀects at the CB
receptors. This suggests that the quinolin-8-yl moiety is crucial
for CB receptor binding, just as the naphthoyl group is
important for the naphthoylindoles through its aromatic
stacking with the receptor.61 The second most abundant
metabolites (the 4- and 5-OH-pentyl-PB-22 metabolites)
showed CB1 receptor activation, which was signiﬁcantly
lower in comparison to that of PB-22, but it was still
signiﬁcantly higher than that induced by our reference
compound, JWH-018 (208.0 and 171.0%, respectively).
Although PB-22, 5F-PB-22, and the hydroxylated metabolites
yielded higher levels of CB2 receptor activation, this activation
did not signiﬁcantly diﬀer from the reference compound, JWH-
018. The N-pentanoic acid PB-22 metabolite did show a
signiﬁcant activation at the CB2 receptor (43.5%), just as N-
pentanoic acid JWH-210, but unexpectedly, it also showed a
signiﬁcant activation of the CB1 receptor compared to basal
levels (25.8%), although this activation remained signiﬁcantly
lower than that induced by JWH-018 and PB-22.
In conclusion, at the evaluated concentration, all hydroxy-
lated metabolites of JWH-122, JWH-210, and PB-22 and their
5-ﬂuoro analogues yielded a similar or sometimes even a
signiﬁcantly higher signal at the CB receptors than the
reference agonist, JWH-018, suggesting a functional relevance
for these compounds. Also, the two N-pentanoic acid
metabolites of JWH-210 and PB-22 consistently showed
activity at one or both CB receptors. This was not expected
based on literature data for the N-pentanoic acid metabolites of
JWH-018 and JWH-073.17,18,20 It is known that SCs quickly
reach maximum concentrations in blood upon use. A high
serum concentration of JWH-018 was reached upon smoking.62
These compounds can have very long terminal half-lives (in the
range of several days), as has been demonstrated in heavy,
chronic users, due to extensive distribution in deeper tissue.63 A
small oral single-dose self-administration pharmacokinetic study
showed that the serum concentration of the metabolites
exceeded that of the parent compound (AM-2201 in that case)
at all time points (1.5−21 h), suggesting a combination of slow
resorption and a fast metabolic transformation upon oral
uptake.64 Although little is known about the concentrations and
half-lives of the metabolites in the blood of users, the presence
of active metabolites may prolong a compound’s psychotropic
and physiological eﬀects, thereby contributing to its toxicity
proﬁle.
Application of the CB Reporter Assays on Natural
Cannabinoids (Δ9THC and CBD) and the Main Phase I
Metabolites of Δ9THC. In addition to SCs, the natural
cannabinoids Δ9THC and cannabidiol (CBD), as well as the
Figure 5. Activation of CB1 receptor (A) and CB2 receptor (B).
Values designated with (a) above error bars denote a signiﬁcant
diﬀerence from the reference compound, JWH-018 (P ≤ 0.05, one-
way ANOVA with Dunnett’s multiple comparison post hoc test).
Values designated with (b) are signiﬁcantly diﬀerent from the
reference compound within a group (groups are separated via vertical
dotted lines). Bars assigned with an (*) are not signiﬁcantly diﬀerent
from basal levels. Data are given as the mean percentage CB receptor
activation (in comparison to the receptor activation of the reference,
JWH-018) ± SEM (n = at least 3 replicates).
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major phase I metabolites of Δ9THC, 11-OH-THC, and
THCCOOH, were evaluated in the CB reporter assay, all at 1
μM concentration (corresponding to 314.5, 314.5, 330.5, and
344.4 ng/mL, respectively). Δ9THC levels in urine are typically
quite low (with 30 ng/mL corresponding to a very high
concentration in heavy users). Urinary concentrations of 11-
OH-THC and THCCOOH can reach up to a few hundred or a
few thousand ng/mL, respectively, in cases with recent heavy
use of cannabis.65−67 Taking as reference the signal obtained
with 1 μM JWH-018, no or only low-level activation was seen
with the natural cannabinoids (Figure 6). THCCOOH shows
no activation at both receptors, either at 1 (Figure 6) or 10 μM
(3144 ng/mL; data not shown), in line with expectations.
Δ9THC shows some activation at CB1 at 1 μM, but it does not
show any activation at CB2. 11-OH-THC shows a low level of
activation at 1 μM at both receptors, which is more pronounced
for CB1 compared to that for CB2. For CBD, which is found
only at low concentrations in the urine of cannabis users
(typically below 10 ng/mL),65 we found no activity at both
receptors at a concentration of 1 μM (data not shown).
However, if oral/oromucosal CBD is administered, (very) high
concentrations may be obtained in the urine,68,69 which may
inﬂuence the signal obtained in our reporter assay.
Application of the CB Reporter Assay as a First-Line
Screening Tool in Urine: Proof of Concept. A promising
future application of the newly developed CB reporter assay
may be its deployment as a ﬁrst-line screening tool,
complementing targeted and untargeted analytical assays and/
or preceding analytical (mass spectrometry based) conﬁrma-
tion. However, the low concentrations of SCs in biological
ﬂuids require high-sensitivity bioassays capable of monitoring
low-nanomolar or subnanomolar (ng/mL) levels of SCs. We
therefore analyzed urine samples of two separate individuals,
spiked with one of the two major metabolites of JWH-210, 4-
and 5-OH-pentyl-JWH-210, at a concentration of 2 ng/mL (5.2
nM). The signals obtained for the spiked urine samples could
be distinguished from the blanks in both the CB1 and CB2
bioassays (Figure 7A−D).
Next, we analyzed three separate blank urine samples and a
genuine urine sample from a user who had consumed a mixture
of JWH-018, JWH-122, and JWH-210 (Figure 7E,F). These
urine samples were split in two parts. One part was subjected to
a semiquantitative LC-MS/MS method, and the other part was
evaluated in our newly developed bioassay. LC-MS/MS analysis
conﬁrmed the presence of metabolites of JWH-018, JWH-122,
and JWH-210 at low- or subnanomolar (ng/mL) levels, thereby
conﬁrming the intake of the aforementioned SCs (Table 2).
Evaluation of the extract with our bioassay resulted in a signal
that could clearly be distinguished from the three control urine
extracts, both for CB1 and CB2 receptors (Figure 7E,F).
Although this result clearly needs to be extended using a larger
panel of authentic samples (which is beyond the scope of the
current study), it indicates the applicability of the CB reporter
assay in the context of screening biological matrices.
■ CONCLUSIONS
We successfully developed a CB receptor activation assay based
on NanoLuc binary technology. This assay combines several
advantages over other CB receptor activation assays as it is a
relatively simple, nonradioactive, sensitive, and homogeneous
method, only requiring basic cell culture equipment and a
standard luminometer. CB receptor activation is measured
proximal to the receptor, which is known to reduce the
incidence of false positives. The developed assay allows real-
time monitoring of receptor activation as the measurement
starts from the moment the test compound is added (which is
in contrast to the commercially available PathHunter assay).
Figure 6. Activation proﬁles at CB1 (A) and CB2 (B) for JWH-018
(red), Δ9THC (blue), 11-OH-THC (green), and THCCOOH
(orange) at a concentration of 1 μM. Data are given as normalized
relative light units (RLU) ± SEM (n = 4, except for JWH-018 for CB2
where n = 2).
Figure 7. (A−D) Analyses of blank and spiked urine samples (2 ng/
mL) of two separate individuals. Shown are the normalized raw data of
the activation proﬁles obtained for CB1 (A, B) and CB2 (C, D) for 4-
OH-pentyl-JWH-210 (A, C) and 5-OH-pentyl-JWH-210 (B, D). (E,
F) Analyses of three separate blank urine samples and a urine sample
from a SC user via the CB reporter assay for CB1 (E) and CB2 (F).
Data are given as normalized relative light units (RLU) ± SEM.
Table 2. Semiquantitative Analysis of Urine Sample of a SC
User via LC-ESI-MS/MS Analysis
drug metabolite semiquantitative result
JWH-018 4-OH-pentyl 1.96 nM (0.7 ng/mL)
5-OH-pentyl 1.12 nM (0.4 ng/mL)
JWH-122 4-OH-pentyl 0.19 nM (0.07 ng/mL)
5-OH-pentyl <0.03 nM (<0.01 ng/mL)
JWH-210 4-OH-pentyl 3.46 nM (1.4 ng/mL)
5-OH-pentyl 0.26 nM (0.1 ng/mL)
5-OH-indole 0.16 nM (0.06 ng/mL)
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The system is also ﬂexible, as the CB receptors can be easily
replaced by another GPCR. The newly developed bioassay was
applied to determine the in vitro activity of several SCs and
their metabolites. We observed that several major metabolites
retain their activity at CB receptors. The high potency and
eﬃcacy of SCs, coupled with their metabolism to a number of
highly active metabolites, might help to explain the distinct
adverse clinical manifestations that have been observed with SC
use.
When considering CB receptors, the developed bioassay may
be used for structure−activity relationship (SAR) studies, but
importantly, it may also be useful as newer NPS legislations
start to implement “activity” (possibly expressed as potency
and/or eﬃcacy) rather than the identity of the drug or its
chemical structure. For example, in 2012, the USA
implemented a legislation that essentially illegalized all SCs as
the new law broadly covers any material or mixture that
contains any amount of “cannabimimetic” agents, their salts,
isomers, or salts of isomers.70 Also, in the UK, a new law on
“legal highs” has been implemented since May 2016.71 The
Psychoactive Substances Act diﬀers from the established
approach to drug control under the Misuse of Drugs Act
1971 as it covers substances by virtue of their psychoactive
properties, as deﬁned by the Advisory Council on the Misuse of
Drugs. Herein, the deﬁnition of a substance producing a
psychoactive eﬀect includes “...(a substance) which produces a
response in in vitro tests qualitatively identical to substances
controlled under the Misuse of Drugs Act 1971...”.72 One of the
receptors included in these in vitro tests, to demonstrate
“psychoactivity” for the purposes of the Psychoactive
Substances Act, is the CB1 receptor.70 It is clear that solely
deducing activity from SAR studies will inevitably lead to
discussions that can be eﬃciently countered by the developed
bioassay.
Our data indicate that the newly developed CB reporter
assay detects CB receptor activation by extracts of biological
matrices in which SCs (or metabolites) are present at low- or
subnanomolar levels of SCs. In the future, this may allow its
deployment as a ﬁrst-line screening tool, complementing
targeted and untargeted analytical assays and/or preceding
analytical (mass spectrometry based) conﬁrmation. Although
the SCs (and metabolites) tested here, as well as other SCs
(and corresponding metabolites, unpublished observations)
were found to be active, we cannot exclude at this point that
there may be SCs for which the major phase I metabolites are
inactive. Also, in cases where there is a considerable delay
between use and sampling, with only trace levels remaining
present, these trace levels may not be suﬃcient to generate a
signal in our bioassay. However, it should be mentioned that
the latter also holds true for analytical assays. For natural
cannabinoids, we cannot exclude that very high urinary levels of
Δ9THC and/or 11-OH-THC may give rise to a positive result
after recent heavy cannabis use, which is not surprising as we
screen for CB activity. In addition, oral or oromucosal use of
products containing high CBD levels may inﬂuence the signal
obtained in our CB reporter assay. However, in both of the
above-mentioned scenarios, we expect that this will not pose a
problem, as heavy use of natural cannabinoids will be easily
picked up by conventional screening assays.
■ ASSOCIATED CONTENT
*S Supporting Information
The Supporting Information is available free of charge on the
ACS Publications website at DOI: 10.1021/acs.anal-
chem.6b02600.
Chemicals and reagents, plasmids and constructs, and
cell culture and transfection information (S1); explan-
ation of correction for solvent controls and for interwell
variability (S2); MRM transitions and optimized MS
parameters for the analytes detected in the urine samples
as well as the internal standards (S3); concentration-
dependent interactions of CB1 and CB2 with βarr2 upon
stimulation with diﬀerent SCs (S4); literature on potency
(EC50) data for Δ9THC and JWH-018 (S5); comparison
of the relative potential of all SCs and metabolites to
activate CB1 and CB2 at 1 μM (S6); antagonistic
properties of several SC metabolites (S7) (PDF)
■ AUTHOR INFORMATION
Corresponding Author
*E-mail: christophe.stove@ugent.be. Tel.: +32 9 264 81 35.
Fax: +32 9 264 81 83.
Notes
The authors declare no competing ﬁnancial interest.
■ ACKNOWLEDGMENTS
The authors acknowledge Dr. Pieter Colin, Huybrecht T’jollyn,
and Robin Michelet for their help in data analysis. The skillful
staﬀ of the Laboratory of Experimental Cancer Research
(headed by Prof. O. De Wever) is acknowledged for their help
with cell culture in the early stages of this project. The Agency
for Innovation by Science and Technology (IWT-Flanders) and
the Bijzonder Onderzoeksfonds (BOF) of Ghent University are
acknowledged for, respectively, granting a Grant for Strategic
Basic Research to A. Cannaert (application number 121504)
and a Ph.D. fellowship to J. Storme (application number
01D31913). The research activities of the Institute of Forensic
Medicine Freiburg were ﬁnancially supported by the
‘Prevention of and Fight against Crime’ program of the
European Commission (JUST/2013/ISEC/DRUGS/AG/
6421).
■ REFERENCES
(1) European Drug Report: Trends and Developments; EMCDDA:
Lisbon, Portugal, 2016.
(2) Fantegrossi, W. E.; Moran, J. H.; Radominska-Pandya, A.;
Prather, P. L. Life Sci. 2014, 97, 45−54.
(3) Vardakou, I.; Pistos, C.; Spiliopoulou, C. Toxicol. Lett. 2010, 197,
157−62.
(4) Seely, K. A.; Lapoint, J.; Moran, J. H.; Fattore, L. Prog. Neuro-
Psychopharmacol. Biol. Psychiatry 2012, 39, 234−43.
(5) Auwar̈ter, V.; Dresen, S.; Weinmann, W.; Müller, M.; Pütz, M.;
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Supplementary Data S-1 
Chemicals and reagents 
Dulbecco’s modified eagle’s medium (DMEM), Opti-MEM
® 
I Reduced Serum Medium, 
penicillin/streptomycin (10.000 IU/ml and 10.000µg/ml), amphotericin B (250µg/ml), glutamine 
(200mM), the restriction enzymes XhoI and EcoRI and the DNA polymerase (Phusion polymerase, a 
polymerase with proofreading activity) were purchased from Thermo Fisher Scientific (Pittsburg, PA, 
USA). The transfection reagent FuGENE
®
 HD and the Nano-Glo Live Cell reagent were purchased from 
Promega (Madison, WI, USA). Primers were procured from Eurofins Genomics (Ebersberg, Germany). 
JWH-122 ((4-methyl-1-naphthyl)-(1-pentyl-1H-lindol-3-yl)methanone), JWH-210 ((4-ethyl-1-
naphthyl)-(1-pentyl-1H-indol-3-yl)methanone), PB-22 (1-pentyl-1H-indole-3-carboxylic acid 8-
quinolinyl ester), their 5-fluoro analogues MAM-2201, EAM-2201, 5F-PB-22, their metabolites and all 
deuterated standards were supplied by Cayman Chemical (Ann Arbor, MI, USA), except JWH-018 
(naphthyl(1-pentyl-1H-indol-3-yl)methanone) was obtained from LGC (Wesel, Germany) and 5-OH-
pentyl-JWH-018 and N-pentanoic acid JWH-018 were purchased from Sigma Aldrich. Fetal bovine 
serum (FBS), poly-D-lysine, formic acid (Rotipuran
®
 ≥ 98 %, p.a.), potassium hydrogen phosphate (≥ 
99 %, p.a.), 2-propanol (Rotisolv
®
 ≥ 98 %, p.a.), acetonitrile (LC-MS grade), ammonium formate 10 M 
(99,995 %) and potassium hydroxide (puriss. p.a. ≥ 86 % (T) pellets) were from Sigma Aldrich 
(Steinheim, Germany). Roche Diagnostics (Mannheim, Germany) supplied the β-glucuronidase (E. coli 
K 12). Deionized water was prepared using a Medica
®
 Pro deionizer from ELGA (Celle, Germany). 
Blank urine samples were donated by one volunteer and tested for the absence of synthetic 
cannabinoid metabolites prior to use. Mobile phase A (0.2 % formic acid and 2 mM ammonium 
formate in water) was freshly prepared prior to LC-MS/MS analysis. Mobile phase B was pure 
acetonitrile. 
 
Plasmids and constructs 
Plasmids containing the human CNR1 (NM_016083) and ARRB2 (NM_004313) coding sequences 
were purchased from Origene Technologies (Rockville, MD, USA). A plasmid containing the human 
CNR2 (NM_001841) coding sequence and the expression vectors, NB MCS-1, NB MCS-2, NB MCS-3 
and NB MCS-4 were kindly provided by respectively, Atwood et al. and Promega (Madison, WI, USA). 
The expression vectors contain the sequences encoding the subunits of the NanoLuc
®
 luciferase 
(LgBiT or SmBiT) and the flexible linker (GSSGGGGSGGGGSSG). All expression plasmids were 
constructed by cloning PCR products, flanked by a unique restriction site, into the respective vectors, 
as described below. All constructs were sequence-verified. 
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To generate the constructs, specific primers were used to PCR-amplify the coding sequence of 
interest, flanked by XhoI or EcoRI restriction sites (see Table S-1a). PCR was performed on 100 pg of 
plasmid DNA using the Phusion High-Fidelity PCR Master Mix with HF Buffer (Thermo Fisher 
Scientific, Pittsburg, PA, USA) according to the manufacturer’s instructions. Reactions were done in a 
Mastercycler™ Nexus Thermal Cycler (Eppendorf, Hamburg, Germany) with an initial denaturation at 
98°C for 30s, 35 cycles of 98°C for 10s (denaturation), Tm for 30s (annealing), and 72°C for 1min 
(elongation), followed by a final extension at 72°C for 5min. The resulting amplification products 
were purified using E.Z.N.A.
®
 MicroElute Cycle-Pure kit (VWR International, Radnor, PA, USA). Both 
the vector and the amplification products were digested with either XhoI or EcoRI restriction 
enzymes (Thermo Fisher Scientific) and purified using E.Z.N.A.
®
 MicroElute Gel Extraction kit (VWR 
International). The digested PCR products were ligated into the corresponding dephosphorylated 
(TSAP Thermosensitive Alkaline Phosphatase, Promega), digested vector (see Table S-1b). After 
transformation of One Shot
®
 Mach1™ T1 Phage-Resistant Chemically Competent E. coli (Thermo 
Fisher Scientific) with the ligated product, the ampicillin-resistant clones were screened by PCR using 
primers complementary to sequences within the insert and sequences of the vector surrounding the 
insert. The integrity of all constructs was confirmed by DNA sequencing. Positively screened colonies 
were grown and used for plasmid isolation, using E.Z.N.A.
®
 Plasmid DNA Mini kit (VWR International). 
Vector POI Primers Tm (°C) 
NB MCS-1 
NB MCS-2 
CB1 Forward ACTCAA CTCGAG ACC ATGAAGTCGATCC 69.6 
 Reverse ACTCAA CTCGAG CC CAGAGCCTCGGC 
CB2 Forward ACTCAA CTCGAG CC CAGAGCCTCGGC 71.0 
 Reverse ACTCAA CTCGAG CC GCAATCAGAGAGG 
βarr2 Forward ACTCAA GAATTC ACC ATGGGGGAGAAACCCGGGACC 71.1 
 Reverse ACTCAA GAATTC CC GCAGAGTTGATCATCATAGTCG 
NB MCS-3 
NB MCS-4 
βarr2 Forward ACTCAA GAATTC A ATGGGGGAGAAACCCGGGACC 69.7 
 Reverse ACTCAA GAATTC TCA GCAGAGTTGATCATCATAGTCG 
Table S-1a. Primers used to clone the protein of interest (POI) in the expression plasmids. Six extra nucleotides precede 
the restriction site (underlined). In some primers, extra nucleotides were added to correct the reading frame. Also the 
Kozak sequence or stop codon (bold) were added, if necessary. The nucleotides in italics are the coding sequences of the 
POI. 
Vector Fusion protein POI Restriction enzyme 
NB MCS-1 POI - Linker - LgBiT CB1 XhoI 
  CB2 XhoI 
  βarr2 EcoRI 
NB MCS-2 POI - Linker - SmBiT CB1 XhoI 
  CB2 XhoI 
  βarr2 EcoRI 
NB MCS-3 LgBiT - Linker - POI βarr2 EcoRI 
NB MCS-4 SmBiT - Linker - POI βarr2 EcoRI 
Table S-1b. Lay-out of the expression vectors and restriction enzymes used for each protein of interest (POI). 
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Cell culture and transfection 
Human embryonic kidney (HEK) 293T cells were routinely maintained at 37°C, 5% CO2, under 
humidified atmosphere in DMEM (high glucose) supplemented with 10% heat-inactivated FBS, 2mM 
of glutamine, 100IU/ml of penicillin, 100µg/ml of streptomycin and 0.25µg/ml of amphotericin B. For 
experiments, HEK 293T cells were plated in 6-well plates at 5x10
5 
cells/well. The next day, cells were 
transiently transfected using FuGENE
®
 HD reagent according to the manufacturer’s protocol (optimal 
ratio of FuGENE:DNA 3:1). Transfection mixes contained 1.65µg of each of the plasmids of interest. 
On the third day, cells were plated on poly-D-lysine-coated 96-well plates at 5x10
4
 cells/well and 
incubated overnight. 
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Supplementary Data S-2 
To evaluate the activity of the different SCs and their metabolites 
To determine the activity of a compound, the absolute signals were corrected for solvent controls 
and for inter-well variability. First, the absolute raw signals (colored lines) were baseline-corrected by 
subtracting the average of the signals from vehicle control samples (black lines) (A to B). Next the 
signals were corrected for the inter-well variability by forcing the curve through 0 (B to C). The AUC 
were calculated and normalized by the AUC of the reference compound, JWH-018. 
 
Figure S-2a: Example of solvent control and inter-well correction. 
 
To assess the activity of the natural cannabinoids and the urinary samples 
Here the absolute raw signals were only corrected for the inter-well variability. The absolute signals 
were corrected by forcing all the curves through the same starting point at time point 0 (A to B). 
  
Figure S-2b: Example of inter-well correction. 
 
 
  
  
S6 
 
Supplementary Data S-3 
Supporting table showing MRM transitions and optimized MS parameters for the analytes detected 
in the urine samples and the used internal standards. 
Analyte 
Q1 Q3 DP EP CE CXP 
Internal standard 
[amu] [amu] [V] [V] [V] [V] 
JWH-018 4-OH-pentyl 358 155 150 5 30 15 D5-JWH-018 4-OH-pentyl 
 358 127 150 5 65 15  
JWH-018 5-OH-pentyl 
 
358 155 150 5 30 15 D5-JWH-018 5-OH-pentyl 
358 127 150 5 65 15  
JWH-122 4-OH-pentyl 372 169 160 7 30 12 D5-JWH-122 5-OH-pentyl 
 
372 141 160 7 57 16  
JWH-122 5-OH-pentyl 372 169 160 7 30 12 D5-JWH-122 5-OH-pentyl 
 372 141 160 7 57 16  
JWH-122 N-pentanoic acid 386 169 190 4 35 13 D4-JWH-018 N-pentanoic acid 
 
386 141 190 4 61 11  
MAM-2201 4-OH-pentyl 390 169 160 11 35 20 D5-JWH-018 5-OH-pentyl 
 390 141 160 11 65 22  
JWH-210 4-OH-pentyl 386 183 160 5 31 15 D7-JWH-018 6-OH-indole 
 386 153 160 5 50 13  
JWH-210 5-OH-indole 386 183 180 4 32 16 D5-JWH-250 
 386 230 180 4 32 18  
JWH-210 5-OH-pentyl 386 183 160 5 31 15 D7-JWH-018 6-OH-indole 
 386 153 160 5 50 13  
JWH-210 N-pentanoic acid 400 183 160 11 35 14 D7-JWH-073 6-OH-indole 
 400 155 160 11 55 20  
PB-22 3-carboxyindole 232 132 130 3 29 16 D7-JWH-073 6-OH-indole 
 232 118 130 3 30 14  
PB-22 4-OH-pentyl 375 144 110 5 35 23 D5-JWH-073 N-butanoic acid 
 375 69 110 5 55 15  
PB-22 5-OH-pentyl 375 230 110 6 45 15 D5-JWH-073 N-butanoic acid 
 375 144 110 5 35 23  
PB-22 N-pentanoic acid 389 244 140 4 30 16 D5-JWH-073 N-butanoic acid 
 389 144 140 4 48 16  
5F-PB-22 3-carboxyindole 250 206 110 3 22 16 D5-JWH-250 4-OH-pentyl 1 
  250 118 110 3 26 13  
D5-JWH-018 4-OH-pentyl 363 155 180 4 25 11 --- 
D5-JWH-018 5-OH-pentyl 363 155 165 10 33 12 --- 
D7-JWH-018 6-OH-indole 367 155 180 4 35 12 --- 
D4-JWH-018 N-pentanoic acid 376 155 170 10 35 7 --- 
D7-JWH-073 6-OH-indole 351 155 170 6 35 12 --- 
D5-JWH-073 N-butanoic acid 363 155 190 5 35 11 --- 
D5-JWH-122 5-OH-pentyl 377 169 185 5 29 14 --- 
D5-JWH-250 341 121 175 10 30 8 --- 
D5-JWH-250 4-OH-pentyl 357 121 150 8 31 15 --- 
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Q1 m/z of the precursor ion 
Q2 m/z of the fragment ion 
DP declustering potential 
EP entrance potential 
CE collision energy 
CXP collision cell exit potential 
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Supplementary Data S-4 
Graphs show the concentration-dependent interaction of CB1 (A) and CB2 (B) with βarr2 upon 
stimulation with different SCs. AUC, area under the curve. Data are given as mean AUC ± SEM (n=5-
6). 
 
 
Figure S-4. The concentration-dependent interaction of CB1 (A) and CB2 (B) with βarr2 upon stimulation with different 
SCs. AUC, area under the curve. Data are given as mean AUC ± SEM (n=5-6).  
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Supplementary Data S-5 
Table S-5 shows the potency (EC50) of Δ
9
THC and JWH-018, determined by different functional assays. 
Drug Functional assay CB1 EC50 (nM) CB2 EC50 (nM) Reference 
Δ9THC GTPγS binding 81 ± 34 
167 ± 84.7 
77.0 ± 29.9 
- 
- 
- 
Breivogel et al. (2001)
1
 
Brents et al. (2011)
2
 
Brents et al. (2012)
3
 
 FLIPR membrane 
potential assay 
250 
172 
1157 
- 
Banister et al. (2015a)
4
 
Banister et al. (2015b)
5
 
 Adenylate cyclase 
inhibition 
- 57.9 ± 19.8 Rajaskaran et al. (2013)
6
 
JWH-018 GTPγS binding 36 
6.8 ± 2.5 
20.2 ± 1.3 
- 
- 
- 
Nakajima et al. (2011)
7
 
Brents et al. (2011)
2
 
De Luca et al. (2013)
8
  
 FLIPR membrane 
potential assay 
102 
18 
133 
22 
Banister et al. (2015a)
4
 
Banister et al. (2015b)
5
 
 Adenylate cyclase 
inhibition 
- 3.6 ± 2.2 Rajaskaran et al. (2013)
6
 
 Internalization assay 2.8 
10.1 
- Atwood et al. (2010)
9
 
Atwood et al. (2011)
10
 
Table S-5. Potency of Δ
9
THC and JWH-018. 
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Supplementary Data S-6 
Drug/metabolite Relative potential of CB1 
activation at 1 µM 
Relative potential of CB2 
activation at 1 µM 
JWH-018 100.0 ± 10.6 (20) 100 ± 17.6 (20) 
4-OH-pentyl JWH-018 90.3 ± 10.9 (4) 102.3 ± 9.5 (4) 
5-OH-pentyl-JWH-018 20.7 ± 5.3 (4) 85.1 ± 13.2 (4) 
5-OH-indole-JWH-018 73.1 ± 18.3 (3) 70.8 ± 24.0 (4) 
6-OH-indole-JWH-018 24.1 ± 4.1 (4) 75.7 ± 4.3 (4) 
N-pentanoic acid JWH-018 0.53 ± 1.77 (4) 15.9 ± 12.6 (4) 
   
JWH-122 173.4 ± 17.6 (4) 94.0 ± 7.5 (4) 
4-OH-pentyl-JWH-122 165.2 ± 13.0 (3) 99.4 ± 4.1 (4) 
MAM-2201 174.7 ± 31.2 (3) 97.4 ± 23.0 (3) 
5-OH-pentyl-JWH-122 99.5 ± 5.9 (4) 96.3 ± 10.9 (4) 
4-OH-pentyl-MAM-2201 173.0 ± 20.2 (4) 87.6 ± 13.5 (4) 
N-pentanoic acid JWH-122 1.4 ± 3.7 (4) 3.6 ± 6.2 (3) 
   
JWH-210 197.9 ± 13.3 (4) 84.5 ± 12.0 (4) 
4-OH-pentyl-JWH-210 179.3 ± 19.0 (3) 115.4 ± 22.2 (4) 
5-OH-pentyl-JWH-210 157.8 ± 12.3 (4) 101.4 ± 12.7 (4) 
5-OH-indole-JWH-210 100.3 ± 13.4 (3) 90.9 ± 18.9 (4) 
EAM-2201 239.7 ± 10.5 (4) 92.4 ± 25.3 (4) 
N-pentanoic acid JWH-210 1.9 ± 1.6 (3) 54.8 ± 7.8 (4) 
   
PB-22 287.0 ± 29.6 (4) 137.6 ± 13.8 (3) 
3-carboxyindole PB-22 1.3 ± 3.6 (4) 1.6 ± 4.3 (3) 
4-OH-pentyl PB-22 208.0 ± 21.2 (4) 144.6 ± 33.0 (4) 
5F-PB-22 278.8 ± 9.2 (3) 131.9 ± 9.3 (4) 
3-carboxyindole 5F-PB-22 3.1 ± 5.0 (4) 4.6 ± 13.1 (4) 
5-OH-pentyl PB-22 171.0 ± 6.9 (3) 142.3 ± 13.3 (4) 
N-pentanoic acid PB-22 25.8 ± 3.4 (4) 43.5 ± 5.3 (4) 
Table S-6. Comparison of relative potential to activate CB1 and CB2 at 1 µM. The data are presented as the % CB 
activation (relative to the receptor activation of JWH-018) ± SEM (number of replicates). 
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Supplementary Data S-7 
 
Figure S-7. Evaluation of antagonistic properties of several SC metabolites. The cells were stimulated with 1 µM of the 
test compound and were incubated for 5 min before adding a fixed concentration of JWH-018 (ED80 concentration). The 
bar ‘JWH-018’ marks the response when no antagonist is present. The bar ‘Rimonabant’ was taken as a positive control 
for CB1 antagonism. Bars assigned with an (*) are not significantly different from basal levels. All test compounds did not 
show antagonistic activity. 
